Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement

Lonza collaborates with Vertex on cell, gene technologies manufacturing

Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)

Ministry of Minority Affairs supports development of unani medicine system

Unani Medicine facilities to be upgraded at Hyderabad, Chennai, Lucknow, Silchar and Bengaluru

Oncodesign Services and Veritas In Silico jointly to develop mRNA-targeted small molecule drugs

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets

Boehringer Ingelheim begins clinical development for fibrotic diseases

‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,

PI Industries announces twin acquisitions into Pharma API & CDMO space

Ascentage presents results of studies underscoring exploratory efforts in potential

The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications

NS Pharma announces FDA clearance to initiate phase II study for an Exon 44 skipping candidate

Study efficacy measures will include the expression of dystrophin protein and motor function.